These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9291443)

  • 1. Introduction: primary prevention against sudden cardiac death.
    Waldo AL; Weisfeldt ML
    Am J Cardiol; 1997 Sep; 80(5B):1F-2F. PubMed ID: 9291443
    [No Abstract]   [Full Text] [Related]  

  • 2. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
    Ferrari R; Cinca J; Marber M
    Eur Heart J; 1999 Mar; 20(6):397-8. PubMed ID: 10213339
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
    Böcker D; Breithardt G
    Am J Cardiol; 1999 Mar; 83(5B):83D-87D. PubMed ID: 10089846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
    Fogoros RN
    Control Clin Trials; 1996 Jun; 17(3 Suppl):37S-46S. PubMed ID: 8877266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large clinical trials in the management of ventricular arrhythmias. Applying group results to individual cases.
    Strobel JS; Epstein AE
    Cardiol Clin; 2000 May; 18(2):337-56, viii. PubMed ID: 10849877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent.
    Fogoros RN
    Am J Cardiol; 1997 Sep; 80(6):762-5. PubMed ID: 9315584
    [No Abstract]   [Full Text] [Related]  

  • 9. [How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti-arrhythmia drug era].
    Seipel L
    Z Kardiol; 1995 Oct; 84(10):787-90. PubMed ID: 7502564
    [No Abstract]   [Full Text] [Related]  

  • 10. Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
    Exner DV; Klein GJ
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):574-7. PubMed ID: 12875415
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden cardiac death prevention: antiarrhythmic drugs and the implantable cardioverter-defibrillator.
    Domanski MJ
    J Interv Cardiol; 1995 Feb; 8(1):9-15. PubMed ID: 10155222
    [No Abstract]   [Full Text] [Related]  

  • 14. What can we expect from prophylactic implantable defibrillators?
    Wilber DJ; Kall JG; Kopp DE
    Am J Cardiol; 1997 Sep; 80(5B):20F-27F. PubMed ID: 9291446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trials: how long should they last?
    Wellens HJ
    Circulation; 2004 Jul; 110(2):107-8. PubMed ID: 15249514
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular tachycardia and sudden cardiac death.
    Reddy PC; Tandon N; Stafford PR
    J La State Med Soc; 1999 May; 151(5):281-7. PubMed ID: 10363484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of arrhythmias in heart failure.
    O'Callaghan PA; Camm AJ
    Eur J Heart Fail; 1999 Jun; 1(2):133-7. PubMed ID: 10937922
    [No Abstract]   [Full Text] [Related]  

  • 20. Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
    Zivin A; Bardy GH
    Am J Cardiol; 1999 Nov; 84(9A):63R-68R. PubMed ID: 10568662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.